

MUTE EXPANDS RANGING IN LEADING US PHARMACY - OVER 1100 NEW STORES ADDED

KEY HIGHLIGHTS:

- Rhinomed extends distribution with CVS, one of America's largest pharmacy chains.
- Mute to be core ranged in additional 1100 new CVS pharmacies in the USA.
- Stock expected to be on shelf from August/September onwards.

June 19 2018, Melbourne, Australia.

Australian nasal and respiratory technology company Rhinomed (ASX:RNO) is pleased to advise investors that it has expanded its relationship with one of America's largest pharmacy retailer - CVS.

The Company has now received initial purchase orders confirming that Mute will be stocked on the shelves of over 1100 new CVS pharmacies across the USA. Rhinomed's Mute technology is currently stocked in approximately 100 CVS stores, so this development represents a 10 fold plus expansion in store count. Mute is now stocked in over 9,000 stores in the US alone.

There are limitations under the order arrangements on the disclosure that Rhinomed can currently provide, as a guide it can provide the following information:

- The company has received purchase orders for over 18,000 units.
- Stock is anticipated to appear on the shelves of stores from August/September 2018.
- Mute is also available online through CVS.com
- Revenues from this expanded store presence are not expected to impact the business until FY19Q2 at the earliest.
- The agreement has no fixed term and can be terminated by either party.
- Pricing details remain confidential.

Rhinomed CEO Michael Johnson commented, *"Rhinomed has been working steadfastly on expanding our retail distribution footprint. Ensuring the Mute technology has a presence on the shelves of all three major pharmacy groups in the USA is a key milestone in our strategy of building a global consumer health brand that is the first touch point for the millions of people who are seeking to improve their sleep."*

While the expanded arrangement and receipt of purchase orders creates potential new market opportunities for Rhinomed and increases the retail reach of the product in the USA, it is not an assurance of ongoing or future retail sales. It is too early to accurately forecast the likely impact of revenues from the Agreement on Rhinomed financial results.

For personal use only

RHINOMED

MAKE EVERY BREATH COUNT

Media Enquiries

Michael Johnson, CEO & Director
+61 (03) 8416 0900
mjohnson@rhinomed.global

Follow us on **Twitter** @rhinomedceo and @theturbinecom

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information go to www.rhinomed.global

About the Mute™

Mute™ is a unique nasal respiratory technology that has been found reduce the volume and frequency of snoring in 75% of users. Mute is easy to use, drug free and fits discreetly inside the nose. Designed to give snoring the silent treatment and made from ultra-soft polymers, Mute gently expands each nostril to increase the volume of air in each breath. By doing so, Mute encourages nasal breathing and reduces the need to open the mouth during sleep, factors critical to a reduction in snoring and better sleep quality. For more information or to purchase online, visit www.mutesnoring.com

Forward Looking Statements

This release includes forward looking statements. Often, but not always, forward looking statements can generally be identified by the use of forward looking words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “continue”, and “guidance”, or other similar words and may include, without limitation statements regarding plans, strategies and objectives of management, anticipated production or construction commencement dates and expected costs or production outputs. Forward looking statements in this release include, but are not limited to, the potential opportunity created by the new distribution channel.

Entry into a distribution arrangement does not guarantee that any particular volume of sales revenue will result.

Forward looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance and achievements to differ materially from any future results, performance or achievements. Relevant factors may include, but are not limited to, consumer preferences, competing products, foreign exchange fluctuations, the counterparty’s acts and omissions, increased costs, changes to government legislation and many other factors. The Company does not give any assurance that the assumptions on which forward looking statements are based will prove to be correct, or that the Company’s business or operations will not be impacted in any material manner by these or other factors not foreseen or foreseeable by the Company or management or that are beyond the Company’s control. Accordingly, readers are cautioned not to place undue reliance on forward looking statements.

For personal use only